MARKET

KTTAW

KTTAW

Pasithea Therapeutics Corp
NASDAQ
0.0097
0.0000
0.00%
Closed 09:30 07/10 EDT
OPEN
0.0097
PREV CLOSE
0.0097
HIGH
0.0097
LOW
0.0097
VOLUME
0
TURNOVER
--
52 WEEK HIGH
0.1198
52 WEEK LOW
0.0034
MARKET CAP
--
P/E (TTM)
-0.0049
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at KTTA last week (0706-0710)?
Weekly Report · 3h ago
Pasithea Therapeutics to attend B. Riley Securities Mind, Muscle & Vision Summit
PUBT · 5d ago
Weekly Report: what happened at KTTA last week (0629-0703)?
Weekly Report · 07/06 09:23
Analysts’ Top Healthcare Picks: Pasithea Therapeutics Corp (KTTA), Xeris Pharmaceuticals (XERS)
TipRanks · 06/30 17:00
Pasithea Therapeutics announces updated data from PAS-004 trial
TipRanks · 06/30 11:15
Pasithea Therapeutics Announces Updated Interim Safety And Clinical Activity Data From Its Trial Evaluating PAS-004 In Patients With MAPK Pathway-Driven Advanced Solid Tumors; PAS-004 Has Been Well-Tolerated, With All Treatment-Related Adverse Events Being Grade 1 Or 2
Benzinga · 06/30 11:04
Pasithea reports positive interim Phase 1 data for PAS-004 in advanced solid tumors, expands dose escalation
PUBT · 06/30 11:03
PASITHEA THERAPEUTICS CORP - INITIATES PILOT FOOD EFFECT STUDY FOR PAS-4 PHARMACOKINETICS
Reuters · 06/30 11:00
More
About KTTAW
Pasithea Therapeutics Corp. is a biotechnology company focused on the discovery, research and development of treatments for central nervous system (CNS) disorders and other diseases. The Company is advancing a pipeline of three therapeutic product candidates, with a focus on its lead product candidate, PAS-004, a macrocyclic mitogen-activated protein kinase, or MEK inhibitor. PAS-004 is a small molecule allosteric inhibitor of MEK 1 and 2 (MEK 1/2) for potential use in the treatment of a range of RASopathies, including neurofibromatosis type 1 (NF1) and a number of oncology indications, among others. Its remaining two programs, PAS-001 and PAS-003, are in the earlier stages of development and are based on novel targets for the treatment of CNS disorders that it believes address limitations in the treatment paradigm of the indications it plans to address, which are amyotrophic lateral sclerosis (ALS) for its PAS-003 program, and schizophrenia for its PAS-001 program.

Webull offers Pasithea Therapeutics Corp stock information, including NASDAQ: KTTAW real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KTTAW stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading KTTAW stock methods without spending real money on the virtual paper trading platform.